Fate Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the lupus treatment candidate FT819.

Cancer research in the U.S. doesn't rely on a single institution or funding stream − it's a complex ecosystem made up of ...

We are navigating political interference, institutional instability, and growing uncertainty across the cancer research ...

Facing White House cuts, New England labs are looking to foundations, industry, and even their university hosts to bankroll ...

While physician-scientists are supported in splitting their time between research and clinical work, nurse-scientists are not ...